Enhancement of Cisplatin Efficacy by Thalidomide in a 9L Rat Gliosarcoma Model

Overview

Journal J Neurooncol

Publisher Springer

Date 2007 May 31

PMID 17534579

Citations 9

Authors

Susan Murphy

Ross A Davey

Xiao-Qing Gu

Miriam C Haywood

Lauren A McCann

Laurence E Mather

Frances M Boyle

Affiliations

Soon will be listed here.

Abstract

With the aim of improving the treatment of glioblastoma multiforme, we investigated the potential of thalidomide to enhance the effectiveness of cisplatin chemotherapy in a rat glioma model. Female F344 rats were implanted with 9L gliosarcoma tumors either intracranially or subcutaneously and treated with 1 mg/kg cisplatin injected i.p. or with 1% thalidomide in the food or with these treatments combined. Cisplatin in combination with thalidomide significantly reduced both the subcutaneous tumor volume at 30 days to 22 +/- 5% (mean +/- SEM, P < 0.001) and the intracranial tumor volume at 18 days to 44 +/- 15% (P < 0.05) of that with cisplatin alone. Thalidomide selectively increased the cisplatin concentration 10-fold in intracranial tumors (P < 0.05) and 2-fold in the subcutaneous tumors (P < 0.05) without increasing its concentration in major organs including brain and kidney. Cisplatin combined with thalidomide caused a significant decrease in vascular endothelial growth factor (VEGF) levels by 73% in intracranial tumors (P < 0.05) and by 50% in subcutaneous tumors (P < 0.05) and caused the level of active hepatic growth factor (a-HGF) to double in both the subcutaneous and intracranial tumors (P < 0.05), suggesting this treatment altered the vasculature in these tumors. We conclude the increased efficacy of cisplatin in the presence of thalidomide was due to the selective increase in cisplatin concentration within the tumors and speculate that this is the result of thalidomide or the cisplatin/thalidomide combination, selectively altering the tumor vasculature. Based on the selective effects of thalidomide on tumor cisplatin concentrations and the resulting increase in efficacy, thalidomide may also increase the efficacy of other drugs that are presently considered ineffective against glioma.

Citing Articles

Synergistic effects of thalidomide and cisplatin are mediated via the PI3K/AKT and JAK1/STAT3 signaling pathways in cervical cancer.

Liu C, Feng H, Song L, Li S, Wu Y, Yang L Oncol Rep. 2022; 48(4).

PMID: 35920185 PMC: 9478987. DOI: 10.3892/or.2022.8384.

Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells.

Zhang X, Luo H Oncol Lett. 2018; 15(3):3313-3320.

PMID: 29435073 PMC: 5778822. DOI: 10.3892/ol.2017.7645.

Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo.

An Y, Guo W, Li L, Xu C, Yang D, Wang S PLoS One. 2015; 10(2):e0116202.

PMID: 25658946 PMC: 4320118. DOI: 10.1371/journal.pone.0116202.

Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect.

Huynh N, Morille M, Bejaud J, Legras P, Vessieres A, Jaouen G Pharm Res. 2011; 28(12):3189-98.

PMID: 21691892 DOI: 10.1007/s11095-011-0501-y.

Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model.

Wang X, Duan X, Yang G, Zhang X, Deng L, Zheng H PLoS One. 2011; 6(4):e18490.

PMID: 21559510 PMC: 3084695. DOI: 10.1371/journal.pone.0018490.

References

Jain R . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7(9):987-9. DOI: 10.1038/nm0901-987. View

Lee C, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J . DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003; 21(14):2732-9. DOI: 10.1200/JCO.2003.01.055. View

Jaeckle K, Eyre H, Townsend J, Schulman S, Knudson H, Belanich M . Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998; 16(10):3310-5. DOI: 10.1200/JCO.1998.16.10.3310. View

Murphy-Poulton S, Boyle F, Gu X, Mather L . Thalidomide enantiomers: determination in biological samples by HPLC and vancomycin-CSP. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 831(1-2):48-56. DOI: 10.1016/j.jchromb.2005.11.023. View

Grossman S . Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomas. Semin Oncol. 2004; 30(6 Suppl 19):19-22. DOI: 10.1053/j.seminoncol.2003.11.035. View

Locke V, Davey R, Davey M . Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells. Br J Haematol. 1999; 106(1):86-91. DOI: 10.1046/j.1365-2141.1999.01494.x. View

Phuphanich S, Baker S, Grossman S, Carson K, Gilbert M, Fisher J . Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol. 2005; 7(2):177-82. PMC: 1871887. DOI: 10.1215/S1152851704000183. View

Li X, Liu X, Wang J, Wang Z, Jiang W, Reed E . Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res. 2003; 23(3B):2481-7. View

Guo P, Xu L, Pan S, Brekken R, Yang S, WHITAKER G . Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res. 2001; 61(23):8569-77. View

10.

Kimler B . The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions. J Neurooncol. 1994; 20(2):103-9. DOI: 10.1007/BF01052721. View

11.

Pardridge W . CNS drug design based on principles of blood-brain barrier transport. J Neurochem. 1998; 70(5):1781-92. DOI: 10.1046/j.1471-4159.1998.70051781.x. View

12.

Henness S, Davey M, Harvie R, Davey R . Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int J Radiat Oncol Biol Phys. 2002; 54(3):895-902. DOI: 10.1016/s0360-3016(02)03037-7. View

13.

Murphy S, Boyle F, Davey R, Gu X, Mather L . Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. J Pharm Pharmacol. 2007; 59(1):105-14. DOI: 10.1211/jpp.59.1.0014. View

14.

Chintala S, Ali-Osman F, Mohanam S, Rayford A, Go Y, Gokaslan Z . Effect of cisplatin and BCNU on MMP-2 levels in human glioblastoma cell lines in vitro. Clin Exp Metastasis. 1997; 15(4):361-7. DOI: 10.1023/a:1018442003163. View

15.

Grossman S, Reinhard C, COLVIN O, Chasin M, Brundrett R, Tamargo R . The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg. 1992; 76(4):640-7. DOI: 10.3171/jns.1992.76.4.0640. View

16.

Ruddy J, Majumdar S . Antitumorigenic Evaluation of Thalidomide Alone and in Combination with Cisplatin in DBA2/J Mice. J Biomed Biotechnol. 2002; 2(1):7-13. PMC: 139116. DOI: 10.1155/S1110724302000359. View

17.

Dunn I, Heese O, Black P . Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol. 2001; 50(1-2):121-37. DOI: 10.1023/a:1006436624862. View

18.

Miller K, Sweeney C, Sledge Jr G . Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001; 19(4):1195-206. DOI: 10.1200/JCO.2001.19.4.1195. View

19.

Boyle F, Beatson C, Monk R, Grant S, Kurek J . The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol. 2002; 48(6):429-34. DOI: 10.1007/s00280-001-0382-6. View

20.

Marx G, Pavlakis N, McCowatt S, Boyle F, LEVI J, Bell D . Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2002; 54(1):31-8. DOI: 10.1023/a:1012554328801. View